Cargando…
Fabrizio VA, Boelens JJ, Mauguen A, et al. Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. Blood Adv. 2022;6(7):1961-1968.
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
The American Society of Hematology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333729/ https://www.ncbi.nlm.nih.gov/pubmed/37368453 http://dx.doi.org/10.1182/bloodadvances.2023010269 |
Ejemplares similares
-
Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy
por: Fabrizio, Vanessa A., et al.
Publicado: (2022) -
Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma
por: Sidana, Surbhi, et al.
Publicado: (2023) -
Fabrizio Lupo
por: Còccioli, Carlo
Publicado: (1971) -
Gill S, Vides V, Frey NV, et al. Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia. Blood Adv. 2022;6(21):5774-5785.
Publicado: (2023) -
Decitabine in combination with fludarabine and cyclophosphamide as a lymphodepletion regimen followed by CD19/CD22 bispecific targeted CAR T-cell therapy significantly improves survival in relapsed/refractory B-ALL patients
por: Ma, Yunju, et al.
Publicado: (2023)